2020 began on a strong note for Novartis, which clocked 13% CER Q1 20 growth. Even after excluding the impact of COVID-19-related forward buying, the growth remained impressive (+9%). Interestingly, the growth was broad-based, with all divisions and most therapeutic areas doing well. However, given the COVID-related criticality, it is difficult to believe that this momentum can be sustained in the coming quarters. Although, Novartis should continue to perform reasonably well by leveraging its
29 Apr 2020
Strong Q1 20, further supported by COVID-19-related buying
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q1 20, further supported by COVID-19-related buying
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
29 Apr 2020 -
Author:
Surbhit Gupta -
Pages:
5
2020 began on a strong note for Novartis, which clocked 13% CER Q1 20 growth. Even after excluding the impact of COVID-19-related forward buying, the growth remained impressive (+9%). Interestingly, the growth was broad-based, with all divisions and most therapeutic areas doing well. However, given the COVID-related criticality, it is difficult to believe that this momentum can be sustained in the coming quarters. Although, Novartis should continue to perform reasonably well by leveraging its